Logo image of SLDB

SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis

NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD

4.54  +0.29 (+6.82%)

After market: 4.45 -0.09 (-1.98%)

Fundamental Rating

3

Taking everything into account, SLDB scores 3 out of 10 in our fundamental rating. SLDB was compared to 558 industry peers in the Biotechnology industry. SLDB has a great financial health rating, but its profitability evaluates not so good. SLDB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLDB had negative earnings in the past year.
SLDB had a negative operating cash flow in the past year.
SLDB had negative earnings in each of the past 5 years.
In the past 5 years SLDB always reported negative operating cash flow.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

SLDB has a Return On Assets of -40.61%. This is comparable to the rest of the industry: SLDB outperforms 56.27% of its industry peers.
SLDB has a better Return On Equity (-47.43%) than 66.85% of its industry peers.
Industry RankSector Rank
ROA -40.61%
ROE -47.43%
ROIC N/A
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

1.3 Margins

SLDB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for SLDB has been increased compared to 1 year ago.
SLDB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SLDB has an improved debt to assets ratio.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SLDB has an Altman-Z score of 0.27. This is a bad value and indicates that SLDB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.27, SLDB is in the better half of the industry, outperforming 64.16% of the companies in the same industry.
SLDB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.27
ROIC/WACCN/A
WACCN/A
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.89 indicates that SLDB has no problem at all paying its short term obligations.
SLDB's Current ratio of 10.89 is amongst the best of the industry. SLDB outperforms 80.29% of its industry peers.
A Quick Ratio of 10.89 indicates that SLDB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.89, SLDB belongs to the top of the industry, outperforming 80.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.89
Quick Ratio 10.89
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.11% over the past year.
Looking at the last year, SLDB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)24.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.81%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.77% yearly.
SLDB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 158.61% yearly.
EPS Next Y37.57%
EPS Next 2Y23.94%
EPS Next 3Y14.77%
EPS Next 5Y11.77%
Revenue Next Year-100%
Revenue Next 2Y-46.7%
Revenue Next 3Y-25.99%
Revenue Next 5Y158.61%

3.3 Evolution

SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2025 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

SLDB's earnings are expected to grow with 14.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.94%
EPS Next 3Y14.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLDB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLID BIOSCIENCES INC

NASDAQ:SLDB (6/6/2025, 8:00:02 PM)

After market: 4.45 -0.09 (-1.98%)

4.54

+0.29 (+6.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners73.99%
Inst Owner Change116.86%
Ins Owners0.97%
Ins Owner Change0.57%
Market Cap351.94M
Analysts85.56
Price Target17.68 (289.43%)
Short Float %13.89%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.84%
Min EPS beat(2)-21.61%
Max EPS beat(2)-4.07%
EPS beat(4)1
Avg EPS beat(4)-7.95%
Min EPS beat(4)-21.61%
Max EPS beat(4)9.9%
EPS beat(8)5
Avg EPS beat(8)0.55%
EPS beat(12)7
Avg EPS beat(12)-3.07%
EPS beat(16)10
Avg EPS beat(16)-0.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.56%
EPS NQ rev (1m)6.15%
EPS NQ rev (3m)20.49%
EPS NY rev (1m)0%
EPS NY rev (3m)0.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.8
TBVpS3.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.61%
ROE -47.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.89
Quick Ratio 10.89
Altman-Z 0.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)75.75%
Cap/Depr(5y)81.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.81%
EPS Next Y37.57%
EPS Next 2Y23.94%
EPS Next 3Y14.77%
EPS Next 5Y11.77%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-46.7%
Revenue Next 3Y-25.99%
Revenue Next 5Y158.61%
EBIT growth 1Y-44.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.75%
EBIT Next 3Y-18.72%
EBIT Next 5Y-14.05%
FCF growth 1Y-26.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.63%
OCF growth 3YN/A
OCF growth 5YN/A